Skip to main content Help with accessibility Skip to main navigation

PCN DOAC Switch Resources

More than 20,000 strokes and 5,000 deaths could be averted after NHS England struck new agreements to expand life-saving blood thinning drugs, NHS England chief executive Amanda Pritchard announced on 16th November 2021.


In March 22 NHSE confirmed two new DOAC indicators for the 2022/23 Investment and Impact Fund (IIF), one specifically looking at the number of patients prescribed edoxaban as a percentage of all DOACs.

To assist PCNs with identifying the correct cohort of patients to switch to edoxaban, and to ensure any switches are done in a safe and co-ordinated manner, the following resources have been put together for clinicians to use.

PCN DOAC switch pack and EMIS web search

Please note: this search will need to be saved on your computer and then imported in within EMIS Web. A tailored auto-report can be created from the search once it has been ran.

PCN Webinar session

In support of the above documents the recording and PowerPoint of the live PCN session held in May 2022 can be found below 

Frequently asked questions

See the latest FAQs for any queries that are not covered in the resources or video recording. If your query is still not answered get in touch with us - details at the bottom of the page.

Other useful documents

DOACs in obesity - position statement for VTE/PE (not AF) but can extrapolated to AF: 


Tips when switching alternative DOACs to edoxaban


NHS England comms regarding apixaban patent



Contact information

If you need help with anything related to the switch, contact your local Medicines Optimisation Team:

Pennine Lancashire  

01282 644799

Fylde coast

Morecambe Bay

Central Lancashire

West Lancashire